Advertisement

Topics

FDA OKs Shire's long-acting ADHD drug

10:56 EDT 22 Jun 2017 | SmartBrief

Shire's Mydayis, or SHP465, has been granted approval by the FDA as a treatment for attention-deficit/hyperactivity disorder  -More

Original Article: FDA OKs Shire's long-acting ADHD drug

NEXT ARTICLE

More From BioPortfolio on "FDA OKs Shire's long-acting ADHD drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...